DE69228061T2 - Sulfatierte glykolipide, die eine galaktose-3-0-sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum - Google Patents

Sulfatierte glykolipide, die eine galaktose-3-0-sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum

Info

Publication number
DE69228061T2
DE69228061T2 DE69228061T DE69228061T DE69228061T2 DE 69228061 T2 DE69228061 T2 DE 69228061T2 DE 69228061 T DE69228061 T DE 69228061T DE 69228061 T DE69228061 T DE 69228061T DE 69228061 T2 DE69228061 T2 DE 69228061T2
Authority
DE
Germany
Prior art keywords
galactose
methods
sulfate
prediabetis
itselves
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69228061T
Other languages
English (en)
Other versions
DE69228061D1 (de
Inventor
Karsten Buschard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A+ Science AB
Original Assignee
A+ Science Invest AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A+ Science Invest AB filed Critical A+ Science Invest AB
Publication of DE69228061D1 publication Critical patent/DE69228061D1/de
Application granted granted Critical
Publication of DE69228061T2 publication Critical patent/DE69228061T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69228061T 1991-05-07 1992-05-07 Sulfatierte glykolipide, die eine galaktose-3-0-sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum Expired - Fee Related DE69228061T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK91846A DK84691D0 (da) 1991-05-07 1991-05-07 Visse glycolipider og specifikke catchere for disse til anvendelse ved profylaxe eller terapi af diabetes, og/eller dermed forbundne komplikationer samt anvendelse af saadanne glycolipider til detektion af oe-celle-antistoffer (ica) i et individ og anvendelse af saadanne catchere til detektion af langerhans-oe-celler i pancreas-praeparater
PCT/DK1992/000146 WO1992019633A1 (en) 1991-05-07 1992-05-07 Sulfated glycolipids, containing a galactose-3-0-sulfate moiety, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications in an individual

Publications (2)

Publication Number Publication Date
DE69228061D1 DE69228061D1 (de) 1999-02-11
DE69228061T2 true DE69228061T2 (de) 1999-05-27

Family

ID=8098211

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228061T Expired - Fee Related DE69228061T2 (de) 1991-05-07 1992-05-07 Sulfatierte glykolipide, die eine galaktose-3-0-sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum

Country Status (9)

Country Link
US (1) US5827828A (de)
EP (1) EP0584175B1 (de)
JP (1) JP3222465B2 (de)
AT (1) ATE175203T1 (de)
AU (1) AU1788892A (de)
DE (1) DE69228061T2 (de)
DK (2) DK84691D0 (de)
ES (1) ES2125898T3 (de)
WO (1) WO1992019633A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
CA2142153A1 (en) * 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
US5663151A (en) * 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
SE9601817D0 (sv) 1996-05-13 1996-05-13 Karsten Buschard Novel glycolipid complexex and their uses
EP0988860B1 (de) * 1997-04-10 2005-01-12 Kirin Beer Kabushiki Kaisha Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittelszur Behandlung von Autoimmunkrankheiten
JP2001527046A (ja) 1997-12-30 2001-12-25 エイプラス サイエンス インベスト アーベー ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および／または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー
SE0000258D0 (sv) * 2000-01-27 2000-01-27 A & Science Invest Ab Pharmaceutical preparation and method for treatment of diabetes
US8367623B2 (en) * 2001-08-16 2013-02-05 Japan As Represented By President Of National Center Of Neurology And Psychiatry Glycolipid and medicine for autoimmune disease containing the same as active ingredient
JP5564672B2 (ja) 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート アジュバント及びその使用方法
FR2926972B1 (fr) * 2008-02-05 2011-03-11 Technologia Appareil de diagnostic precoce du syndrome du canal carpien et procede et dispositif d'acquisition de l'information relative a la sensibilite cutanee du doigt du patient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288706A (en) * 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others

Also Published As

Publication number Publication date
DE69228061D1 (de) 1999-02-11
ATE175203T1 (de) 1999-01-15
DK0584175T3 (da) 1999-08-30
JPH06506943A (ja) 1994-08-04
DK84691D0 (da) 1991-05-07
US5827828A (en) 1998-10-27
WO1992019633A1 (en) 1992-11-12
AU1788892A (en) 1992-12-21
JP3222465B2 (ja) 2001-10-29
ES2125898T3 (es) 1999-03-16
EP0584175B1 (de) 1998-12-30
EP0584175A1 (de) 1994-03-02

Similar Documents

Publication Publication Date Title
Kochian et al. Potassium transport in corn roots: I. Resolution of kinetics into a saturable and linear component
Bowers Retreat from sanity: The structure of emerging psychosis.
DE69228061T2 (de) Sulfatierte glykolipide, die eine galaktose-3-0-sulfate-gruppierung enthalten, und spezifische fänger für diese für die verwendung in der prophylaxe oder therapie der prädiabetis, diabetis und/oder damit zusammenhängender komplikationen in einem individuum
Grandjean et al. Psychological dysfunctions in lead-exposed workers: relation to biological parameters of exposure
BR7608467A (pt) Processo e dispositivo para teste de gravidez,bem como processo para detecao de condicoes fisiologicas associadas a presenca de gonadotropinas na urina ou no soro
Soffer et al. Immunological factors and post coital test in unexplained infertility.
Rachman et al. Is incomplete fear-reduction followed by a return of fear?
Paulev et al. Motor nerve conduction velocity in asymptomatic lead workers
EP0259183A3 (de) Verfahren zur Kontrolle der Genauigkeit und der Präzision von Empfindlichkeitstesten
Stork et al. Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose
Lorente et al. A simple and reproducible method to evaluate granulocyte adherence
Magro Blocking of histamine release from human basophils in vitro by the ATPase inhibitor, ethacrynic acid.
Speert et al. Abnormalities of in vitro lymphocyte response to mitogens in diabetic children during acute ketoacidosis
Wang et al. Plasma arginase concentration measured by an enzyme-linked immunosorbent assay (ELISA) in normal adult population
Weissgarten et al. Induction of suppressor cells in normal lymphocytes by uremic serum
Richards et al. Thyroid hormone and conditioning.
GR980300023T1 (en) Means for treating auto-immune diseases and method of treatment
Sechrest et al. Criminal activity, wages earned, and drug use after two years of methadone treatment.
JPS55119755A (en) Processor providing test instruction function
JPS5443096A (en) Sample vessel for electrolyte analyser
KR950703658A (ko) Hiv감염자 및 그들의 처치 정도를 확인하는 방법 및 진단물질
Lu Solution of elastoplastic contact problem by boundary element method and mathematical programming technique
Temeck et al. Bronchopulmonary dysplasia and allergy.
IE873143L (en) HOMOGENEOUS SHEEP TllTS AS AN INTERMEDIATE FOR THE¹PREPARATION OF HUMAN Tllts, AND THE USE THEREOF
Ernst THE RADIATION SENSITIVITY OF CELL NUCLEOPROTEINS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee